FDA Inspection 1025203 — Aerie Pharmaceuticals, Inc.
The FDA completed an inspection of Aerie Pharmaceuticals, Inc. on Aug 23, 2017 in Bedminster, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 23, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Bedminster, NJ (United States)
Additional Details
Sponsor, Contract Research Organization